"In February 2020, Apabetalone became the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation, for a major cardiovascular indication, to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy."
top of page
Recent Posts
See AllRakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...
bottom of page